New development of Immune checkpoints blockade in cancer immunotherapy
Immunotherapy has become the main stream in cancer treatment nowadays. It includes T cell, NK cell targeted therapy, as well as antibody targeted therapy and its derivatives. Recently immune checkpoints blockade (ICB) has been developed, which are said to be a better method in treatment. The release...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
EDP Sciences
2019-01-01
|
| Series: | E3S Web of Conferences |
| Online Access: | https://www.e3s-conferences.org/articles/e3sconf/pdf/2019/57/e3sconf_chinabiofilms18_01022.pdf |
| _version_ | 1818955422054219776 |
|---|---|
| author | Wu Feixuan |
| author_facet | Wu Feixuan |
| author_sort | Wu Feixuan |
| collection | DOAJ |
| description | Immunotherapy has become the main stream in cancer treatment nowadays. It includes T cell, NK cell targeted therapy, as well as antibody targeted therapy and its derivatives. Recently immune checkpoints blockade (ICB) has been developed, which are said to be a better method in treatment. The release of negative regulators of immune activation has resulted in unprecedented rates of long-lasting tumor responses in patients with a variety of cancers. This can be achieved by antibodies blocking the cytotoxic T lymphocyte–associated protein 4 (CTLA-4), the programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PDL-1) pathway or the lymphocyte-activated gene-3 (LAG-3) pathway, either alone or in combination. Improvement of treatment benefits from the research in molecular mechanisms of ICB. For example, mechanism of LAG-3 and its valid ligands is unclear, which leads to a misunderstanding that the antibody might be ineffective. After finding these results demonstrating that fibrinogen-like protein 1(FGL1) is an important functional ligand of LAG-3, it reveals the role of this LAG 3-FGL1 pathway in tumor immunity. Although there are some potential side effects, these therapies turn out to have lots of positive effects on most patients. Therefore, this review summarizes the latest advances, hoping that it may have a great contribution to the cancer treatment. |
| first_indexed | 2024-12-20T10:37:48Z |
| format | Article |
| id | doaj.art-f14ffb1b7c294ad7a21be8edafc964d3 |
| institution | Directory Open Access Journal |
| issn | 2267-1242 |
| language | English |
| last_indexed | 2024-12-20T10:37:48Z |
| publishDate | 2019-01-01 |
| publisher | EDP Sciences |
| record_format | Article |
| series | E3S Web of Conferences |
| spelling | doaj.art-f14ffb1b7c294ad7a21be8edafc964d32022-12-21T19:43:36ZengEDP SciencesE3S Web of Conferences2267-12422019-01-011310102210.1051/e3sconf/201913101022e3sconf_chinabiofilms18_01022New development of Immune checkpoints blockade in cancer immunotherapyWu FeixuanImmunotherapy has become the main stream in cancer treatment nowadays. It includes T cell, NK cell targeted therapy, as well as antibody targeted therapy and its derivatives. Recently immune checkpoints blockade (ICB) has been developed, which are said to be a better method in treatment. The release of negative regulators of immune activation has resulted in unprecedented rates of long-lasting tumor responses in patients with a variety of cancers. This can be achieved by antibodies blocking the cytotoxic T lymphocyte–associated protein 4 (CTLA-4), the programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PDL-1) pathway or the lymphocyte-activated gene-3 (LAG-3) pathway, either alone or in combination. Improvement of treatment benefits from the research in molecular mechanisms of ICB. For example, mechanism of LAG-3 and its valid ligands is unclear, which leads to a misunderstanding that the antibody might be ineffective. After finding these results demonstrating that fibrinogen-like protein 1(FGL1) is an important functional ligand of LAG-3, it reveals the role of this LAG 3-FGL1 pathway in tumor immunity. Although there are some potential side effects, these therapies turn out to have lots of positive effects on most patients. Therefore, this review summarizes the latest advances, hoping that it may have a great contribution to the cancer treatment.https://www.e3s-conferences.org/articles/e3sconf/pdf/2019/57/e3sconf_chinabiofilms18_01022.pdf |
| spellingShingle | Wu Feixuan New development of Immune checkpoints blockade in cancer immunotherapy E3S Web of Conferences |
| title | New development of Immune checkpoints blockade in cancer immunotherapy |
| title_full | New development of Immune checkpoints blockade in cancer immunotherapy |
| title_fullStr | New development of Immune checkpoints blockade in cancer immunotherapy |
| title_full_unstemmed | New development of Immune checkpoints blockade in cancer immunotherapy |
| title_short | New development of Immune checkpoints blockade in cancer immunotherapy |
| title_sort | new development of immune checkpoints blockade in cancer immunotherapy |
| url | https://www.e3s-conferences.org/articles/e3sconf/pdf/2019/57/e3sconf_chinabiofilms18_01022.pdf |
| work_keys_str_mv | AT wufeixuan newdevelopmentofimmunecheckpointsblockadeincancerimmunotherapy |